Anti-cancer Effects of MW-03, a Novel Indole Compound, by Inducing 15-Hydroxyprostaglandin Dehydrogenase and Cellular Growth Inhibition in the LS174T Human Colon Cancer Cell Line.

Persistent Link:
http://hdl.handle.net/10150/626040
Title:
Anti-cancer Effects of MW-03, a Novel Indole Compound, by Inducing 15-Hydroxyprostaglandin Dehydrogenase and Cellular Growth Inhibition in the LS174T Human Colon Cancer Cell Line.
Author:
Seira, Naofumi; Yanagisawa, Naoki; Suganami, Akiko; Honda, Takuya; Wasai, Makiko; Regan, John W; Fukushima, Keijo; Yamaguchi, Naoto; Tamura, Yutaka; Arai, Takayoshi; Murayama, Toshihiko; Fujino, Hiromichi
Affiliation:
Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol
Issue Date:
2017-10
Publisher:
PHARMACEUTICAL SOC JAPAN
Citation:
Anti-cancer Effects of MW-03, a Novel Indole Compound, by Inducing 15-Hydroxyprostaglandin Dehydrogenase and Cellular Growth Inhibition in the LS174T Human Colon Cancer Cell Line. 2017, 40 (10):1806-1812 Biol. Pharm. Bull.
Journal:
Biological & pharmaceutical bulletin
Rights:
© 2017 The Pharmaceutical Society of Japan
Collection Information:
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
Abstract:
Increases in the expression of prostaglandin E2 (PGE2) are widely known to be involved in aberrant growth in the early stage of colon cancer development. We herein demonstrated that the novel indole compound MW-03 reduced PGE2-induced cAMP formation by catalization to an inactive metabolite by inducing 15-hydroxyprostaglandin dehydrogenase through the activation of peroxisome proliferator-activated receptor-γ. MW-03 also inhibited colon cancer cell growth by arresting the cell cycle at the S phase. Although the target of MW-03 for cell cycle inhibition has not yet been identified, these dual anti-cancer effects of MW-03 itself and/or its leading compound(s) on colon cancer cells may reduce colon cancer development and, thus, have potential as a novel treatment for the early stage of this disease.
ISSN:
1347-5215
PubMed ID:
28966256
DOI:
10.1248/bpb.b17-00458
Keywords:
indole compound; MW-03; prostaglandin E-2; 15-hydroxyprostaglandin dehydrogenase; peroxisome proliferator-activated receptor-gamma; colon cancer
Version:
Final published version
Sponsors:
Ministry of Education, Culture, Sports, Science and Technology of Japan [JP17K08308]; Center of Excellence (COE) program from Chiba University of Japan
Additional Links:
https://www.jstage.jst.go.jp/article/bpb/40/10/40_b17-00458/_article

Full metadata record

DC FieldValue Language
dc.contributor.authorSeira, Naofumien
dc.contributor.authorYanagisawa, Naokien
dc.contributor.authorSuganami, Akikoen
dc.contributor.authorHonda, Takuyaen
dc.contributor.authorWasai, Makikoen
dc.contributor.authorRegan, John Wen
dc.contributor.authorFukushima, Keijoen
dc.contributor.authorYamaguchi, Naotoen
dc.contributor.authorTamura, Yutakaen
dc.contributor.authorArai, Takayoshien
dc.contributor.authorMurayama, Toshihikoen
dc.contributor.authorFujino, Hiromichien
dc.date.accessioned2017-11-13T15:58:30Z-
dc.date.available2017-11-13T15:58:30Z-
dc.date.issued2017-10-
dc.identifier.citationAnti-cancer Effects of MW-03, a Novel Indole Compound, by Inducing 15-Hydroxyprostaglandin Dehydrogenase and Cellular Growth Inhibition in the LS174T Human Colon Cancer Cell Line. 2017, 40 (10):1806-1812 Biol. Pharm. Bull.en
dc.identifier.issn1347-5215-
dc.identifier.pmid28966256-
dc.identifier.doi10.1248/bpb.b17-00458-
dc.identifier.urihttp://hdl.handle.net/10150/626040-
dc.description.abstractIncreases in the expression of prostaglandin E2 (PGE2) are widely known to be involved in aberrant growth in the early stage of colon cancer development. We herein demonstrated that the novel indole compound MW-03 reduced PGE2-induced cAMP formation by catalization to an inactive metabolite by inducing 15-hydroxyprostaglandin dehydrogenase through the activation of peroxisome proliferator-activated receptor-γ. MW-03 also inhibited colon cancer cell growth by arresting the cell cycle at the S phase. Although the target of MW-03 for cell cycle inhibition has not yet been identified, these dual anti-cancer effects of MW-03 itself and/or its leading compound(s) on colon cancer cells may reduce colon cancer development and, thus, have potential as a novel treatment for the early stage of this disease.en
dc.description.sponsorshipMinistry of Education, Culture, Sports, Science and Technology of Japan [JP17K08308]; Center of Excellence (COE) program from Chiba University of Japanen
dc.language.isoenen
dc.publisherPHARMACEUTICAL SOC JAPANen
dc.relation.urlhttps://www.jstage.jst.go.jp/article/bpb/40/10/40_b17-00458/_articleen
dc.rights© 2017 The Pharmaceutical Society of Japanen
dc.subjectindole compounden
dc.subjectMW-03en
dc.subjectprostaglandin E-2en
dc.subject15-hydroxyprostaglandin dehydrogenaseen
dc.subjectperoxisome proliferator-activated receptor-gammaen
dc.subjectcolon canceren
dc.titleAnti-cancer Effects of MW-03, a Novel Indole Compound, by Inducing 15-Hydroxyprostaglandin Dehydrogenase and Cellular Growth Inhibition in the LS174T Human Colon Cancer Cell Line.en
dc.typeArticleen
dc.contributor.departmentUniv Arizona, Coll Pharm, Dept Pharmacol & Toxicolen
dc.identifier.journalBiological & pharmaceutical bulletinen
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen

Related articles on PubMed

All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.